Mauna Kea Technologies Supports Clinical Research Evaluating the Use of Cellvizio on COVID-19 Patients with Respiratory Insufficiency
Mauna Kea Technologies Supports Clinical Research Evaluating the Use of Cellvizio on COVID-19 Patients with Respiratory Insufficiency Regulatory News: Mauna Kea Technologies (Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, is supporting research to determine if Cellvizio can be effective in severe acute and/or long COVID-19 patients suffering from lingering respiratory complications. Mauna Kea Technologies is offering in-kind funding to researchers evaluating what role Cellvizio may...
Source: finanznachrichten.de